Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL2354846 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL1728893 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL4920513 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL7537653 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL5679533 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL703430 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL509509 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL2392102 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL37333 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL2350111 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140990-A1 | PYRAZOLE FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117917398-A | Ionizable lipid compound, nucleic acid drug molecule delivery system and application | 华中师范大学 | 2024-04-23 | — | — | CN | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4347603-A1 | SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS | Erasca, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-113004305-B | Macrocyclic compounds, their preparation and use | 赛诺哈勃药业（成都）有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114736264-B | Tau protein visual PROTAC degradation compound and preparation method and application thereof | 华东师范大学 | 2024-04-02 | — | — | CN | disclosed |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | disclosed |
| EP-2612860-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-10 | — | — | EP | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2471786-A1 | AMINOPYRAZOLE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120053213-A1 | 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PREPARATION METHODS AND USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-03-01 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2351739-A1 | THE 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS THE INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PRAPARATION METHODS AND USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2011-08-03 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2002002568-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | KNOLL GMBH (DE) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053213-A1 | 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PREPARATION METHODS AND USES THEREOF | PNP, DPYD, TYMP | TSHR 3350/4885TDP1 172/4885TP53 3919/4885 |
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | TSHR 807/4885TDP1 3591/4885TP53 460/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | TSHR 3412/4885TDP1 446/4885TP53 58/4885 |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | KRAS, NRAS, HRAS | TSHR 2399/4885TDP1 1501/4885TP53 4/4885 |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | TSHR 1092/4885TDP1 3804/4885TP53 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.